Mark E. Sullivan

Mark E. Sullivan

Auto-generated profile, based on publicly available information

Mark E. Sullivan

Department of Urology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MPMark P. Purdue
Mark P. Purdue
DDDiptavo Dutta
Diptavo Dutta
MMMitchell J. Machiela
Mitchell J. Machiela
BGBryan R. Gorman
Bryan R. Gorman
TWTimothy Winter
Timothy Winter
SCStephen J. Chanock
Stephen J. Chanock

5 September 2006 in BJU International
Verified
Journal Article
Closed access
PDF file
JMJon‐Paul Meyer
Jon‐Paul Meyer
GDGeorge H. Delves
George H. Delves
MSMark E. Sullivan
Mark E. Sullivan
SKStephen R. Keoghane
Stephen R. Keoghane

1 November 2011 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
TPThinn P. Pwint
Thinn P. Pwint
VMValentine Macaulay
Valentine Macaulay
IRIan S.D. Roberts
Ian S.D. Roberts
MSMark Sullivan
Mark Sullivan
APAndrew Protheroe
Andrew Protheroe

1 November 2000 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
MKM. A. Khan
M. A. Khan
RCR. C. Calvert
R. C. Calvert
MSM. E. Sullivan
M. E. Sullivan
CTC. S. Thomson
C. S. Thomson
FMFaiz Mumtaz
Faiz Mumtaz
DMD. P. Mikhailidis
D. P. Mikhailidis
Erectile dysfunction (ED) is a common problem, particularly in older men. The production of penile erection involves an interplay between autonomic nerves and locally released vasoactive mediators. Endothelin-1 (ET-1) is a peptide released from endothelium in the corpus cavernosum, which causes smooth muscle contraction. Recent studies have investigated the physiological significance of ET-1 in the control of erectile function and it may play a role in detumescence. There is also much evidence to link ET-1 to risk factors for ED. ET-1 antagonists may prove beneficial in the treatment of ED and also in prevention of long term deterioration of erectile function. These antagonists may also find a role when used in combination with agents, which are established for the treatment of ED.

31 January 2022 in BJU International
Verified
Journal Article
Open access
PDF file
ALAaron Leiblich
Aaron Leiblich
SGStefanos Gorgoraptis
Stefanos Gorgoraptis
ASAlexandra Shaw
Alexandra Shaw
FAFarhan Ahmad
Farhan Ahmad
ACAngus Campbell
Angus Campbell
MSMark E. Sullivan
Mark E. Sullivan
Click on the article title to read more.